



QUICK TIPS FOR SELF-INJECTING AT HOME

Before using, you should receive training from your healthcare provider on how to inject SKYRIZI.

BEFORE INJECTING:



Leave the carton at room temperature and out of direct sunlight for 30 to 90 mins before injecting.

Place the following on a clean, flat surface:

- ✓ SKYRIZI Instructions for Use
- ✓ 1 SKYRIZI Pen (included)
- ✓ 1 alcohol swab
- ✓ 1 cotton ball or gauze pad
- ✓ FDA-cleared sharps disposal container



Wash and dry your hands.

STEPS FOR SELF-INJECTING:



1 PICK INJECTION SITE

Pick a place on either front of thigh or stomach. If you choose your stomach, ensure you inject at least 2 inches away from your belly button. Grab a store-bought alcohol swab and clean your skin in a circular motion.



2 PULL OFF THE CAP, THROW IT AWAY

Check the liquid through the inspection window. It should look clear to slightly yellow and may contain tiny white or clear particles. It's also normal to see bubbles.



3 PLACE AND PRESS ON THE INJECTION SITE

Once you've found the right spot, turn the SKYRIZI Pen so the white needle sleeve points toward the injection site. Pinch the skin at your injection site to make a raised area and hold it firmly.

Before proceeding to Step 4, make sure the white needle sleeve is pressed down against the raised injection site before pressing the green button, otherwise the Pen will not activate.



4 PRESS GREEN BUTTON DOWN

Press the Pen down against the raised injection site and maintain pressure throughout the injection. Press the green button, which will make a "click" sound, and hold the pen in place. You'll know the injection is complete when you hear a second click or the yellow indicator has filled the inspection window. This takes up to 15 seconds.

AFTER INJECTING:



Dispose of the SKYRIZI Pen in an FDA-cleared leak-resistant sharps disposal container.



Download the SKYRIZI Complete App in the App Store® or Google Play™ to log your injection and add a reminder for your next dose in 12 weeks.



Scan this QR code with your smartphone camera to watch a video on how to inject SKYRIZI, or visit www.SKYRIZIVideo.com



Need help or have questions?

Call your **Skyrizi Complete Nurse Ambassador*** at **1.866.SKYRIZI (1.866.759.7494)** Live Chat on SKYRIZIComplete.com can also connect you with a nurse 24/7

Skyrizi COMPLETE

*Nurse Ambassadors are provided by AbbVie and do not work under the direction of your health care professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.

Safety Considerations¹

SKYRIZI may cause serious side effects, including:

- **Serious allergic reactions:** Stop using SKYRIZI and get emergency medical help right away if you get any symptoms of a serious allergic reaction.
- **Infections:** SKYRIZI may increase your risk of infections. Before starting treatment, your doctor should check you for infections and tuberculosis. Tell your doctor right away if you have an infection or symptoms of one.

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. Also, tell your doctor if you plan to or recently received a vaccine.

Please see Uses and additional Important Safety Information on next page. Please see accompanying full Prescribing Information, including Medication Guide, or visit www.rxabbvie.com/pdf/skyrizi_pi.pdf, and discuss with your doctor.

Skyrizi[®]
risankizumab-rzaa

USES AND IMPORTANT SAFETY INFORMATION ABOUT SKYRIZI® (risankizumab-rzaa)¹

SKYRIZI Uses¹

SKYRIZI is a prescription medicine used to treat adults:

- with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).
- with active psoriatic arthritis (PsA).

Important Safety Information¹

What is the most important information I should know about SKYRIZI® (risankizumab-rzaa)?

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions:

- Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:
 - fainting, dizziness, feeling lightheaded (low blood pressure)
 - trouble breathing or throat tightness
 - swelling of your face, eyelids, lips, mouth, tongue, or throat
 - chest tightness
 - skin rash, hives
 - itching

Infections:

SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.

- Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
 - fever, sweats, or chills
 - muscle aches
 - weight loss
 - cough
 - warm, red, or painful skin or sores on your body different from your psoriasis
 - diarrhea or stomach pain
 - shortness of breath
 - burning when you urinate or urinating more often than normal
 - blood in your mucus (phlegm)

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.

Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:

- have any of the conditions or symptoms listed in the section “**What is the most important information I should know about SKYRIZI?**”
- have an infection that does not go away or that keeps coming back.
- have TB or have been in close contact with someone with TB.
- have recently received or are scheduled to receive an immunization (vaccine). Medications that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine.
- are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk.
- become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-302-2161 to enroll in this registry.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SKYRIZI?

SKYRIZI may cause serious side effects. See “What is the most important information I should know about SKYRIZI?”

The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include:

upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.

These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help.

Visit AbbVie.com/myAbbVieAssist to learn more.

Reference: 1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.

Please see accompanying full Prescribing Information, including Medication Guide, or visit www.rxabbvie.com/pdf/skyrizi_pi.pdf, and discuss with your doctor.

abbvie

© 2023 AbbVie. All rights reserved. SKYRIZI® and its design are registered trademarks of AbbVie Biotechnology Ltd. US-SKZ-220557 January 2023


Skyrizi®
risankizumab-rzaa